Cilastatin Sodium; Imipenem; Relebactam Patent Expiration
Cilastatin Sodium; Imipenem; Relebactam is Used for treating complicated urinary tract infections. It was first introduced by Merck Sharp And Dohme Corp A Sub Of Merck And Co Inc
Cilastatin Sodium; Imipenem; Relebactam Patents
Given below is the list of patents protecting Cilastatin Sodium; Imipenem; Relebactam, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Recarbrio | US8487093 | β-lactamase inhibitors | Mar 21, 2033 | Msd Merck Co |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cilastatin Sodium; Imipenem; Relebactam's patents.
Latest Legal Activities on Cilastatin Sodium; Imipenem; Relebactam's Patents
Given below is the list recent legal activities going on the following patents of Cilastatin Sodium; Imipenem; Relebactam.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Eligible | 23 Nov, 2022 | US8487093 |
| FDA Final Eligibility Letter Critical | 01 Aug, 2022 | US8487093 |
| transaction for FDA Determination of Regulatory Review Period | 05 Nov, 2021 | US8487093 |
| transaction for FDA Determination of Regulatory Review Period | 04 Nov, 2021 | US8487093 |
| Second letter to regulating agency to determine regulatory review period | 12 Jul, 2021 | US8487093 |
| Letter from FDA or Dept of Agriculture re PTE application | 04 Jan, 2021 | US8487093 |
| Initial letter Re: PTE Application to regulating agency | 29 Sep, 2020 | US8487093 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Sep, 2020 | US8487093 |
| Post Issue Communication - Certificate of Correction | 07 Oct, 2015 | US8487093 |
| SE - Mail Supplemental Examination Petition Granted | 13 Aug, 2015 | US8487093 |
Cilastatin Sodium; Imipenem; Relebactam's Family Patents
